Peng Men
Overview
Explore the profile of Peng Men including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Qiu T, Li H, Sun T, Men P, Cui X, Liu C, et al.
J Clin Pharm Ther
. 2020 Aug;
45(5):1134-1142.
PMID: 32743898
What Is Known And Objective: Thalidomide is used off-label for the treatment of inflammatory bowel disease (IBD) and not as a first-line treatment option. The instructions clearly state that thalidomide...
12.
Men P, Qu S, Song Z, Liu Y, Li C, Zhai S
Diabetes Ther
. 2020 Jun;
11(8):1745-1755.
PMID: 32562244
Introduction: The aim of this study was to compare the efficacy, safety and cost-utility (from the Chinese health insurance perspective) of lixisenatide and insulin regimens in patients with type 2...
13.
Yi Z, Men P, Qu S, Li C, Yu X, Zhai S
Expert Rev Pharmacoecon Outcomes Res
. 2020 Apr;
20(3):313-320.
PMID: 32293194
Background: Both amisulpride and olanzapine are leading treatments for schizophrenia in China. This study aimed to investigate the long-term cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in...
14.
Yang W, Men P, Xue H, Jiang M, Luo Q
Front Oncol
. 2020 Mar;
10:197.
PMID: 32211312
The combination of immune checkpoint inhibitors (ICIs) and chemotherapy can improve clinical outcomes in the treatment of various tumors, but may also be associated with more adverse events (AEs). We...
15.
Luo Q, Men P, Liu Z, Zhai S, Jiang M
Front Oncol
. 2019 Sep;
9:774.
PMID: 31475116
Previous studies have preliminarily identified the non-inferior efficacy for reducing skeletal-related event (SRE) rates between de-escalated (Q12w) and standard (Q3-4w) bone-targeting agents therapy in malignant tumor patients with bone metastases....
16.
Men P, Li C, Zhai S, Qu S
Curr Med Res Opin
. 2019 Aug;
36(2):213-217.
PMID: 31469303
To compare the cost per responder of lixisenatide versus insulin glulisine once daily (basal-plus) and three times daily (basal-bolus) on top of basal insulin for the treatment of patients with...
17.
Men P, Qu S, Luo W, Li C, Zhai S
Diabetes Obes Metab
. 2019 Aug;
22(1):107-115.
PMID: 31469217
Aims: To evaluate the comparative efficacy and safety of lixisenatide combined with basal insulin (BI) vs intensive premix insulin (premix), BI plus prandial insulin with the main meal (basal-plus) or...
18.
Liu X, Men P, Wang B, Cai G, Zhao Z
Lipids Health Dis
. 2019 Jun;
18(1):144.
PMID: 31208420
Background: Dipeptidyl peptidase-4 inhibitors (DPP-4i) are emerging glucose-lowering agents through interacting with DPP-4 substrate, impact of which on systemic inflammation in type 2 diabetes mellitus (T2DM) remains unknown. This study...
19.
Men P, Yi Z, Li C, Qu S, Xiong T, Yu X, et al.
BMC Psychiatry
. 2018 Sep;
18(1):286.
PMID: 30185173
Background: Amisulpride was introduced into China in 2010 as a second-generation atypical antipsychotic, while olanzapine has been on the market since 1999 as one of the leading treatments for schizophrenia...
20.
Men P, Li X, Tang H, Zhai S
PLoS One
. 2018 May;
13(5):e0197321.
PMID: 29787616
Objective: To evaluate the comparative efficacy and safety of saxagliptin for type 2 diabetes (T2D). Methods: A systematic search of PubMed, Embase, the Cochrane Library, Web of Science, ClinicalTrials.gov and...